Literature DB >> 2193627

Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever.

F Bella1, B Font, S Uriz, T Muñoz, E Espejo, J Traveria, J A Serrano, F Segura.   

Abstract

We undertook a randomized clinical trial comparing therapeutic efficacy of the 1-day doxycycline regimen with the 5-day josamycin regimen for Mediterranean spotted fever. All 59 patients recovered uneventfully, and results did not significantly differ between the two schedules. One-day doxycycline therapy is an effective, easy, and inexpensive treatment. Josamycin is a useful therapeutic alternative that may be particularly convenient for pregnant women and patients with a history of allergy to tetracyclines.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2193627      PMCID： PMC171727          DOI： 10.1128/AAC.34.5.937

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever.

Authors:  F Gudiol; R Pallares; J Carratala; F Bolao; J Ariza; G Rufi; P F Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: plaque assay and microplaque colorimetric assay.

Authors:  D Raoult; P Roussellier; G Vestris; J Tamalet
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

3.  In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay.

Authors:  D Raoult; P Roussellier; V Galicher; R Perez; J Tamalet
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Comparative, randomized trial of one-day doxycycline versus 10-day tetracycline therapy for Mediterranean spotted fever.

Authors:  F Bella-Cueto; B Font-Creus; F Segura-Porta; E Espejo-Arenas; P López-Parés; T Muñoz-Espín
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

Review 5.  Mediterranean spotted fever: a cooperative study of 227 cases.

Authors:  B Font-Creus; F Bella-Cueto; E Espejo-Arenas; R Vidal-Sanahuja; T Muñoz-Espin; M Nolla-Salas; A Casagran-Borrell; J Mercade-Cuesta; F Segura-Porta
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

6.  Tetracyclines and permanent teeth: the relation between dose and tooth color.

Authors:  E R Grossman; A Walchek; H Freedman
Journal:  Pediatrics       Date:  1971-03       Impact factor: 7.124

7.  Erythromycin versus tetracycline for treatment of Mediterranean spotted fever.

Authors:  T Muñoz-Espin; P López-Parés; E Espejo-Arenas; B Font-Creus; I Martinez-Vila; J Travería-Casanova; F Segura-Porta; F Bella-Cueto
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

8.  In vitro evaluation of josamycin, spiramycin, and erythromycin against Rickettsia rickettsii and R. conorii.

Authors:  D Raoult; P Roussellier; J Tamalet
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191
  8 in total
  15 in total

Review 1.  Host, pathogen and treatment-related prognostic factors in rickettsioses.

Authors:  E Botelho-Nevers; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-26       Impact factor: 3.267

Review 2.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Analysis of fluorescent protein expression in transformants of Rickettsia monacensis, an obligate intracellular tick symbiont.

Authors:  Gerald D Baldridge; Nicole Burkhardt; Michael J Herron; Timothy J Kurtti; Ulrike G Munderloh
Journal:  Appl Environ Microbiol       Date:  2005-04       Impact factor: 4.792

4.  In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.

Authors:  J M Rolain; M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Randomized Trial of Clarithromycin for Mediterranean Spotted Fever.

Authors:  Esperança Anton; Tomas Muñoz; Francisco Javier Travería; Gemma Navarro; Bernat Font; Isabel Sanfeliu; Ferran Segura
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

6.  Prospective Cohort Study of Single-Day Doxycycline Therapy for Mediterranean Spotted Fever.

Authors:  Elena Espejo; Marta Andrés; Maria-Consol Garcia; Anna Fajardo; Josefa Pérez; Feliu Bella
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 7.  Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies.

Authors:  Steven C Buckingham
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

8.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 9.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

10.  In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Authors:  D Raoult; P Bres; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.